TSHA Q3 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$27M

EPS (Diluted)

$-0.65

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$32M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$111M

Total Liabilities

$100M

Stockholders' Equity

$11M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$25M	-$51M	+49.8%
Net Income	-$27M	-$51M	+48.2%